ABSTRACT
BACKGROUND AND AIMS: Compared to in-hospital births, the long-term outcome of children born out-of-hospital, planned or unplanned, is poorly studied. This study aimed to examine mortality and morbidity by seven years of age in children born out-of-hospital compared to those born in-hospital. METHODS: This study was registered retrospectively and included 790 136 children born in Finland between 1996 and 2013. The study population was divided into three groups according to birth site: in-hospital (n = 788 622), planned out-of-hospital (n = 176), and unplanned out-of-hospital (n = 1338). Data regarding deaths, hospital visits, reimbursement of medical expenses, and disability allowances was collected up to seven years of age or by the year-end of 2018. The association between birth site and childhood morbidity was determined using multivariable-adjusted Cox hazard regression analysis. RESULTS: No deaths were reported during the first seven years after birth in the children born out-of-hospital. The percentage of children with hospital visits due to infection by seven years of age was lower in those born planned out-of-hospital and in the combined planned out-of-hospital and unplanned out-of-hospital group compared to those born in-hospital. Furthermore, the percentage of children with hospital visits and who received disability allowances due to neurological or mental disorders was higher among those born unplanned out-of-hospital and out-of-hospital in total when compared to those born in-hospital. In the multivariable-adjusted Cox proportional hazard regression analysis, the hazard ratio for hospital visits due to asthma and/or allergic diseases (HR 0.84; 95% CI 0.72-0.98) was lower in children born out-of-hospital when compared to those born in-hospital. A similar decreased risk was found due to infections (HR 0.76; 95% CI 0.68-0.84). However, the risk for neurological or mental health disorders was similar between the children born in-hospital and out-of-hospital. CONCLUSIONS: Morbidity related to asthma or allergic diseases and infections by seven years of age appeared to be lower in children born out-of-hospital. Birth out-of-hospital seemed to not be associated with increased risk for neurological morbidity nor early childhood mortality. Our study groups were small and heterogeneous and because of this the results need to be interpreted with caution.
Subject(s)
Hospitals/statistics & numerical data , Parturition/physiology , Asthma/mortality , Child , Finland , Humans , Hypersensitivity/mortality , Infant, Newborn , Morbidity , Retrospective StudiesABSTRACT
BACKGROUND: Acute myocarditis is an inflammatory disease of the heart mostly diagnosed in young people, which can present as sudden death. The etiology includes infectious agents (mostly viruses), systemic diseases and toxins. We aim to characterize infants and children with myocarditis at post-mortem presenting as sudden deaths. METHODS: Retrospective evaluation of 813 post-mortems in infants and children dying suddenly and unexpectedly between 2009-2019. Data retrieved included histological features, microbiology and clinical history. RESULTS: 23 of 813 post-mortems reviewed corresponded to acute myocarditis and 1 to dilated cardiomyopathy related to remote Parvovirus infection. PCR identified enterovirus (7), parvovirus (7 cases, 2 also with HHV6 and 1 case with EVB), Influenza A (1), Parainfluenza type 3 (1). Two cases corresponded to hypersensitivity myocarditis, 1 was Group A Streptococcus and 5 idiopathic myocarditis. Enterovirus was frequent in infants (7/10), and in newborns was associated with meningoencephalitis or congenital myocarditis. More than 50% were less than 2 years of age and all remained clinically unsuspected. CONCLUSION: Myocarditis represents almost 3% of all sudden pediatric deaths. Enterovirus and parvovirus were the most common viruses. This retrospective analysis showed that patients experienced viral symptoms but remained unsuspected, highlighting the need for more clinical awareness of myocarditis.
Subject(s)
Death, Sudden, Cardiac/etiology , Myocarditis/diagnosis , Acute Disease , Adolescent , Child , Child, Preschool , Eosinophilia/complications , Eosinophilia/diagnosis , Eosinophilia/mortality , Female , Humans , Hypersensitivity/complications , Hypersensitivity/diagnosis , Hypersensitivity/mortality , Infant , Infant, Newborn , Male , Myocarditis/etiology , Myocarditis/mortality , Retrospective Studies , Risk Factors , United Kingdom/epidemiology , Virus Diseases/complications , Virus Diseases/diagnosis , Virus Diseases/mortalityABSTRACT
Allergic reactions to stings of Hymenoptera species may be severe and are potentially fatal deviations of the immunological response observed in healthy individuals. However, venom-specific immunotherapy (VIT) is an immunomodulatory approach able to cure venom allergy in the majority of affected patients. An appropriate therapeutic intervention and the efficacy of VIT not only depend on a conclusive diagnosis, but might also be influenced by the patient-specific manifestation of the disease. As with other diseases, it should be borne in mind that there are different endotypes and phenotypes of venom allergy, each of which require a patient-tailored disease management and treatment scheme. Reviewed here are different endotypes of sting reactions such as IgE-mediated allergy, asymptomatic sensitization or a simultaneous presence of venom allergy and mast cell disorders including particular considerations for diagnosis and therapy. Additionally, phenotypical manifestations of venom allergy, as e.g. differences in age of onset and disease severity, multiple sensitization or patients unsusceptible to therapy, are described. Moreover, biomarkers and diagnostic strategies that might reflect the immunological status of the patient and their value for therapeutic guidance are discussed. Taken together, the increasing knowledge of different disease manifestations in venom hypersensitivity and the growing availability of diagnostic tools open new options for the classification of venom allergy and, hence, for personalized medical approaches and precision medicine in Hymenoptera venom allergy.
Subject(s)
Arthropod Venoms/immunology , Bites and Stings/therapy , Desensitization, Immunologic , Hymenoptera/immunology , Hypersensitivity/therapy , Precision Medicine , Animals , Bites and Stings/diagnosis , Bites and Stings/immunology , Bites and Stings/mortality , Humans , Hypersensitivity/diagnosis , Hypersensitivity/immunology , Hypersensitivity/mortality , Immunologic Tests , Phenotype , Precision Medicine/adverse effects , Predictive Value of Tests , Risk Assessment , Risk Factors , Treatment OutcomeABSTRACT
Summary: Background. Anaphylaxis is a potentially fatal medical emergency. The frequency of hospital admissions for anaphylaxis seems to be increasing in the recent decades. Objective. Characterize the patients admitted for anaphylaxis to the adult emergency department (ED) of a tertiary care hospital over a 10-year period, discriminating aetiologies, clinical features and therapy administered. Methods. Retrospective, descriptive and inferential study, evaluating age, sex, Manchester triage system, suspected allergen, site of allergen exposure, comorbidities, cofactors, clinical findings and symptoms, treatment and management. Patients admitted between January 2007 and December 2016 were included. Results. Forty-three patients were enrolled: 23 males, mean age 54.3 ± 16.2 years, n = 22 had history of allergic disease. Two patients were triaged as non-urgent. The most frequently suspected causes of anaphylaxis were: drugs (33%, n = 14), Hymenoptera venoms (23%, n = 10), foods (21%, n = 9) and iodinated contrast products (12%, n = 5). Adrenaline was used in 88% of the episodes (n = 38), 55% of which (n = 21) intramuscularly. Mortality was registered in one case. At discharge, adrenaline auto-injector was prescribed in 7% (n = 3) of the patients, and Allergy and Clinical Immunology consultation (ACIC) was requested in 65% of the episodes (n = 28). Statistically significant associations (p minor 0.05) were established: a, anaphylaxis to drugs associated with a low intramuscular adrenaline use and with frequent oxygen therapy; b, anaphylaxis to food associated with intramuscular adrenaline administration; c, anaphylaxis to Hymenoptera venom associated with male sex; and d, anaphylaxis to iodinated contrasts associated with referral to ACIC and with shock. All obese patients developed shock. Conclusions. Anaphylaxis is a life-threatening condition that requires early recognition. Although most patients received adrenaline, administration was not always performed by the recommended route and only a few patients were prescribed adrenaline auto-injector.
Subject(s)
Allergens/immunology , Anaphylaxis/epidemiology , Hypersensitivity/epidemiology , Adult , Anaphylaxis/drug therapy , Anaphylaxis/mortality , Animals , Arthropod Venoms/immunology , Emergency Service, Hospital , Epinephrine/therapeutic use , Female , Food , Humans , Hymenoptera , Hypersensitivity/drug therapy , Hypersensitivity/mortality , Male , Middle Aged , Pharmaceutical Preparations , Portugal/epidemiology , Retrospective Studies , Tertiary Care CentersABSTRACT
BACKGROUND: The presence of psoriasis is currently considered by the European Society of Cardiology cardiovascular prevention guidelines of 2016 as one possible cardiovascular risk factor. Patients with psoriasis and concomitant coronary artery disease treated by means of percutaneous coronary interven-tion (PCI) are a fairly large subgroup of patients that have been usually omitted in mainstream research. The aim herein, was to identify the incidence of psoriasis, baseline characteristics and periprocedural outcome with a special focus on procedural complications in patients undergoing percutaneous coronary procedures. METHODS: All consecutive patients who had either coronary angiography or coronary angiography with immediate PCI in Poland in 2014 and 2015 were included. Patients were assigned to two groups based on previous diagnosis: with psoriasis and without psoriasis. Clinical outcome was defined as any periprocedural death. RESULTS: There were 405,078 patients included in this analysis. Psoriasis (moderate or severe) was di-agnosed in 1507 (0.4%) of them. Psoriasis was an independent predictor of allergic reaction occurrence (odds ratio [OR] 6.02; 95% confidence interval [CI] 1.44-25.22; p = 0.014). After propensity score adjustment, psoriasis remained a significant predictor of allergic reaction (OR 5, 95% CI 1.2-20.7; p = 0.0245). There were no differences in rates of periprocedural deaths in patients with or without psoriasis (death: 0.95% vs. 0.62%, p > 0.05). CONCLUSIONS: Severe or moderate psoriasis is an independent risk factor for the occurrence of allergic reaction during percutaneous coronary procedures. There were no differences in periprocedural mortal-ity and complications in patients with versus those without psoriasis.
Subject(s)
Coronary Artery Disease/therapy , Hypersensitivity/epidemiology , Percutaneous Coronary Intervention/adverse effects , Psoriasis/epidemiology , Aged , Big Data , Coronary Artery Disease/diagnosis , Coronary Artery Disease/mortality , Female , Humans , Hypersensitivity/diagnosis , Hypersensitivity/mortality , Incidence , Male , Middle Aged , Percutaneous Coronary Intervention/mortality , Poland/epidemiology , Psoriasis/diagnosis , Psoriasis/mortality , Registries , Risk Assessment , Risk Factors , Severity of Illness Index , Treatment OutcomeABSTRACT
OBJECTIVES: The immune response during sepsis remains poorly understood and is likely influenced by the host's preexisting immunologic comorbidities. Although more than 20% of the U.S. population has an allergic-atopic disease, the type 2 immune response that is overactive in these diseases can also mediate beneficial pro-resolving, tissue-repair functions. Thus, the presence of allergic immunologic comorbidities may be advantageous for patients suffering from sepsis. The objective of this study was to test the hypothesis that comorbid type 2 immune diseases confer protection against morbidity and mortality due to acute infection. DESIGN: Retrospective cohort study of patients hospitalized with an acute infection between November 2008 and January 2016 using electronic health record data. SETTING: Single tertiary-care academic medical center. PATIENTS: Admissions to the hospital through the emergency department with likely infection at the time of admission who may or may not have had a type 2 immune-mediated disease, defined as asthma, allergic rhinitis, atopic dermatitis, or food allergy, as determined by International Classification of Diseases, 9th Revision, Clinical Modification codes. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of 10,789 admissions for infection, 2,578 (24%) had a type 2 disease; these patients were more likely to be female, black, and younger than patients without type 2 diseases. In unadjusted analyses, type 2 patients had decreased odds of dying during the hospitalization (0.47; 95% CI, 0.38-0.59, p < 0.001), while having more than one type 2 disease conferred a dose-dependent reduction in the risk of mortality (p < 0.001). When adjusting for demographics, medications, types of infection, and illness severity, the presence of a type 2 disease remained protective (odds ratio, 0.55; 95% CI, 0.43-0.70; p < 0.001). Similar results were found using a propensity score analysis (odds ratio, 0.57; 95% CI, 0.45-0.71; p < 0.001). CONCLUSIONS: Patients with type 2 diseases admitted with acute infections have reduced mortality, implying that the type 2 immune response is protective in sepsis.
Subject(s)
Hypersensitivity/complications , Hypersensitivity/mortality , Infections/complications , Infections/mortality , Acute Disease , Adult , Aged , Cohort Studies , Female , Hospitalization , Humans , Infections/immunology , Male , Middle Aged , Retrospective Studies , Risk AssessmentABSTRACT
PURPOSE OF REVIEW: To review and understand the impact of the outcome measures of allergic and hypersensitivity conditions for the WHO's International Classification of Diseases (ICD) and its impact in the management of anaphylaxis and identify potential strategies to improve patients' care and prevention. RECENT FINDINGS: The pioneer chapter addressed to allergic and hypersensitivity conditions in the 11th version of the WHO's ICD is the result of the evidence-based academic technical actions consistently following of collaborations of the allergy community and integrated international initiatives in order to reach quality outcomes measures of allergies worldwide. SUMMARY: Allergic and hypersensitivity conditions are increasing worldwide, however, they have never been well represented in the international classification systems, such as the ICD. The ALLERGY in ICD-11 initiative has been launched in 2012 in order to gather a better representation of these conditions in the ICD-11. As a result of the evidence-based academic technical actions acknowledged by the Joint Allergy Academies and the WHO, the pioneer chapter Allergy and hypersensitivity conditions has been constructed. This framework can be considered a milestone in the history of the allergy specialty. More reliable, accurate and comparable epidemiological data will be able to provide a big picture of these conditions and will support improvements in many levels of the health system. As knowledge derived from populations is key information for more realistic decision-making, the construction of the new section addressed to allergic and hypersensitivity conditions in the ICD-11 will allow the collection of more accurate epidemiological data to support quality management of patients, and better facilitate healthcare planning to implement public health measures to prevent and reduce the morbidity and mortality attributable to these conditions.
Subject(s)
Hypersensitivity/classification , Hypersensitivity/epidemiology , International Classification of Diseases/trends , World Health Organization , History, 20th Century , History, 21st Century , Humans , Hypersensitivity/history , Hypersensitivity/mortality , International Classification of Diseases/historyABSTRACT
BACKGROUND: We previously reported that exposure to a farming environment is allergy-protective, while high proportions of neonatal immature/naïve CD5+ B cells and putative regulatory T cells (Tregs) are risk factors for development of allergic disease and sensitization up to 3 years of age. OBJECTIVE: To examine if B and T cell maturation are associated with allergic disease and farming environment over the first 8 years in life. METHODS: In the prospective FARMFLORA study, including both farming and non-farming families, 48 of 65 children took part in the 8-year follow-up study. Various B and T cell maturation variables were examined in blood samples obtained at several occasions from birth to 8 years of age and related to doctors' diagnosed allergic disease and sensitization, and to farming environment. RESULTS: We found that the incidence of allergic disease was lower among farmers' compared to non-farmers' children during the 8-year follow-up period, and that farmers' children had higher proportions of memory B cells at 8 years of age. Moreover, a high proportion of neonatal CD5+ B cells was a risk factor for and may predict development of allergic disease at 8 years of age. A high proportion of Tregs was not protective against development of these conditions. CONCLUSION AND CLINICAL RELEVANCE: High proportions of neonatal naïve B cells remained as a risk factor for allergic disease in school-aged children. Thus, the accelerated B cell maturation observed among farmers' children may be crucial for the allergy-protective effect of a farming environment.
Subject(s)
B-Lymphocytes/cytology , B-Lymphocytes/immunology , Cell Differentiation/immunology , Hypersensitivity/diagnosis , Hypersensitivity/immunology , Aged , Animals , B-Lymphocytes/metabolism , Child , Environmental Exposure/adverse effects , Female , Humans , Hypersensitivity/mortality , Immunization , Immunoglobulin E/blood , Immunoglobulin E/immunology , Immunologic Memory , Kaplan-Meier Estimate , Male , Middle Aged , Risk Factors , Skin Tests , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolismSubject(s)
Anti-Asthmatic Agents/adverse effects , Cardiovascular Diseases/epidemiology , Cerebrovascular Disorders/epidemiology , Hypersensitivity/therapy , Omalizumab/adverse effects , Anti-Asthmatic Agents/therapeutic use , Cardiovascular Diseases/etiology , Cardiovascular Diseases/mortality , Cerebrovascular Disorders/etiology , Cerebrovascular Disorders/mortality , Child , Double-Blind Method , Humans , Hypersensitivity/epidemiology , Hypersensitivity/mortality , Omalizumab/therapeutic use , Placebo Effect , Randomized Controlled Trials as Topic , Survival AnalysisABSTRACT
BACKGROUND: Venom immunotherapy is efficient to desensitize people suffering from insect sting allergies. However, the numerous injections required over several years and important risks of severe side reactions complicate the widespread use of immunotherapy. In the search for novel approaches to blunt the overwhelming pro-allergic Th2 response, we evaluated the therapeutic efficacy of a treatment based on a denatured form of the major allergen, phospholipase A2, associated with microbubbles (PLA2denat -MB) in a mouse model of honeybee venom allergy. METHODS: Antibodies measured by ELISA, T-cell responses assessed by CFSE-based proliferation assays and ELISA, and basophil degranulation were examined after PLA2denat -MB-based therapeutic treatment of sensitized mice. Mice were challenged with a lethal dose of PLA2 to evaluate protection against anaphylaxis. RESULTS: Therapeutic subcutaneous administration of two different PLA2denat -MB formulations, in contrast to PLA2denat alone, reduced allergic symptoms and protected all mice from anaphylaxis-mediated death after allergen challenge. At the functional level, the use of PLA2denat decreased IgE-mediated basophil degranulation as compared to the native form of the allergen. In comparison with PLA2denat alone, both PLA2denat -MB formulations decreased allergen-specific Th2 CD4 T-cell reactivity. At the mechanistic level, PLA2denat -MB containing 20% palmitic acid and PEG induced PLA2-specific IgA and increased Foxp3(+) Treg frequencies and TGF-ß production, whereas the formulation bearing 80% palmitic acid triggered the production of IFN-γ, IgG2a, and IgG3. CONCLUSIONS: In contrast to conventional PLA2 subcutaneous immunotherapy, the therapeutic administration of PLA2-MB treatment to mice that already had established allergy to PLA2 protects all subsequently challenged animals.
Subject(s)
Allergens/immunology , Bee Venoms/immunology , Bees/immunology , Hypersensitivity/immunology , Hypersensitivity/therapy , Microbubbles , Phospholipases A2/administration & dosage , Anaphylaxis/immunology , Anaphylaxis/therapy , Animals , Antibody Specificity/immunology , Basophils/immunology , Basophils/metabolism , Cell Degranulation/immunology , Cytokines/metabolism , Desensitization, Immunologic , Disease Models, Animal , Female , Hypersensitivity/mortality , Immune Tolerance , Immunoglobulin E/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Insect Bites and Stings/immunology , Mice , Rats , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolismABSTRACT
PURPOSE: The hallmark of Primary immunodeficiencies (PID) is unusual infection, although other immunological non-infectious manifestations such as autoimmunity, allergy and cancer are often present. Most published reports focus on one disease or defect groups, so that a global prevalence of non-infectious manifestations of PID is hard to find. We aimed to describe the clinical features of our pediatric patients with PID, as well as the frequency and evolution of allergy, cancer and autoimmunity. METHODS: We reviewed all the available charts of patients being followed for PID from 1991 to the spring of 2012 at the National Institute of Pediatrics, Mexico City, to describe their demographic, clinical and laboratory features. Their diagnoses were established by pediatric immunologists in accordance to ESID criteria, including routine immunological workup and specialized diagnostic assays. We divided patients by decade of diagnosis to analyze their survival curves. RESULTS: There were 168 charts available, from which we excluded one duplicate and six equivocal diagnoses. We studied the charts of 161 PID patients (68% male, 86% alive), mostly from the center of the country, with a positive family history in 27% and known consanguinity in 11%. Eighty percent of the patients were diagnosed during the last decade. Current median age was 124 months; median age at onset of infections, 12 months; median age at diagnosis, 52 months; median age at death, 67.5 months. Severe infection and bleeding were the cause of 22 deaths. Eighty-six percent of all patients had at least one infection, while non-infectious manifestations had a global prevalence of 36%, namely: autoimmunity 19%, allergies 17%, and cancer 2.4%. Survival curves were not significantly different when compared by decade of diagnosis. CONCLUSIONS: Compared to other registry reports, we found a lower prevalence of antibody defects, and of associated allergy and cancer. We could only locate two isolated IgA deficiencies and four cases of cancer among our PID patients. Although antibody defects are the most prevalent group (30%), the distribution we found is similar to that reported in Iran, Kuwait, Egypt and Taiwan, with a close 27% share for phagocyte defects, and 26% for the formerly called "well-defined" syndromes. Of note, autoimmune and inflammatory complications are high among our patients with chronic granulomatous disease, as has been reported in both the United States and Japan, but not in Europe.
Subject(s)
Autoimmune Diseases/epidemiology , Hypersensitivity/epidemiology , Immunologic Deficiency Syndromes/epidemiology , Infections/epidemiology , Neoplasms/epidemiology , Autoimmune Diseases/diagnosis , Autoimmune Diseases/mortality , Child , Consanguinity , Female , Humans , Hypersensitivity/diagnosis , Hypersensitivity/mortality , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/mortality , Infections/diagnosis , Infections/mortality , Male , Mexico , Neoplasms/diagnosis , Neoplasms/mortality , Phenotype , Prevalence , Survival AnalysisABSTRACT
Physicians think of mast cells and IgE primarily in the context of allergic disorders, including fatal anaphylaxis. This 'bad side' of mast cells and IgE is so well accepted that it can be difficult to think of them in other contexts, particularly those in which they may have beneficial functions. However, there is evidence that mast cells and IgE, as well as basophils (circulating granulocytes whose functions partially overlap with those of mast cells), can contribute to host defense as components of adaptive type 2 immune responses to helminths, ticks and certain other parasites. Accordingly, allergies often are conceptualized as "misdirected" type 2 immune responses, in which IgE antibodies are produced against any of a diverse group of apparently harmless antigens, as well as against components of animal venoms. Indeed, certain unfortunate patients who have become sensitized to venoms develop severe IgE-associated allergic reactions, including fatal anaphylaxis, upon subsequent venom exposure. In this review, we will describe evidence that mast cells can enhance innate resistance to reptile or arthropod venoms during a first exposure to such venoms. We also will discuss findings indicating that, in mice which survive an initial encounter with venom, acquired type 2 immune responses, IgE antibodies, the high affinity IgE receptor (FcÉRI), and mast cells can contribute to acquired resistance to the lethal effects of both honeybee venom and Russell's viper venom. These findings support the hypothesis that mast cells and IgE can help protect the host against venoms and perhaps other noxious substances.
Subject(s)
Allergens/immunology , Anaphylaxis/immunology , Bee Venoms/adverse effects , Immunoglobulin E/immunology , Mast Cells/immunology , Anaphylaxis/genetics , Anaphylaxis/metabolism , Anaphylaxis/mortality , Animals , Basophils/immunology , Basophils/metabolism , Disease Resistance , Humans , Hypersensitivity/genetics , Hypersensitivity/immunology , Hypersensitivity/metabolism , Hypersensitivity/mortality , Immunity, Innate , Mast Cells/metabolism , Models, AnimalABSTRACT
BACKGROUND: Epstein-Barr virus (EBV)-associated T/natural-killer lymphoproliferative disorders form a group of diseases that includes classical and systemic hydroa vacciniforme (HV) and hypersensitivity to mosquito bites (HMB). Patients with systemic HV (sHV) and HMB often have a poor prognosis, although little is known about the prognostic factors. OBJECTIVES: To elucidate the prognostic factors of HV and HMB. METHODS: We studied clinicopathological manifestations, routine laboratory findings, anti-EBV titres, EBV DNA load and EBV-encoded gene expression, including expression of BZLF1, in 50 patients with classical HV (cHV), sHV, HMB only and HMB with HV (HMB + HV), and further analysed 30 patients who were available for follow-up. RESULTS: The median age of disease onset was 5 years (range 1-74). A follow-up study indicated that fatal outcomes were observed in three of eight patients with sHV, two of six patients with HMB only, and two of five patients with HMB + HV. The main causes of death were complications from haematopoietic stem-cell transplantation and multiorgan failure. There were no fatalities among the 11 patients with cHV. Univariate analysis revealed two poor prognostic indicators: (i) onset age > 9 years and (ii) the expression of an EBV-encoded immediate-early gene transcript, BZLF1 mRNA, in the skin lesions (P < 0·001 and P = 0·003, respectively). CONCLUSIONS: No prognostic correlation was observed in EBV-infected lymphocyte subsets, anti-EBV antibody titres or EBV DNA load. Late onset and EBV reactivation are both related to more severe phenotypes of the disease, and thus may predict a poor prognosis.
Subject(s)
Culicidae , Epstein-Barr Virus Infections/mortality , Hydroa Vacciniforme/mortality , Hypersensitivity/mortality , Insect Bites and Stings/mortality , Adolescent , Adult , Age of Onset , Aged , Animals , Child , Child, Preschool , Female , Herpesvirus 4, Human , Humans , Hydroa Vacciniforme/virology , Hypersensitivity/virology , Immune Reconstitution Inflammatory Syndrome/virology , Infant , Insect Bites and Stings/virology , Kaplan-Meier Estimate , Leukocytes, Mononuclear/virology , Male , Middle Aged , Prognosis , Young AdultABSTRACT
Increasing number of patients with allergy observed in recent years is accompanied with increasing number of health encounters due to acute allergy. The sudden beginning and unpredictable course characterize acute allergy. These factors can be fatal for patient and must be treated immediately. Allergic rhinitis, allergic conjunctivitis, acute urticaria, angioedema and anaphylaxis refer to diseases based on acute allergy. The most dangerous diseases, characterized by fatal conditions, are generalised urticaria, angioedema and anaphylaxis. Knowledge of first aid principles is the most important factor of effective treatment because quickness of allergy progression requires prompt decisions. Use of the whole complex of modern therapeutic possibilities is the most important and durable. Modern methods of first aid for acute allergy, based on recommendations from foreign and domestic publications, are given in the article.
Subject(s)
Hypersensitivity , Military Medicine/methods , Acute Disease , Female , Humans , Hypersensitivity/diagnosis , Hypersensitivity/mortality , Hypersensitivity/therapy , Male , Military Medicine/standards , RussiaABSTRACT
BACKGROUND AIMS: Umbilical cord blood transplantation (CBT) is an effective treatment for benign and malignant diseases. Late effects of CBT are not well described in the literature. In the present study, we present our experience of new-onset allergies in long-term survivors after CBT. METHODS: After an initial patient had a severe peanut allergic reaction after CBT, all CBT patients were prospectively followed for new allergy development. Fifty patients received CBT between March 2006 and June 2011. RESULTS: The median follow-up after CBT was 447 days (range, 12-2022). At the time of analysis, 30 patients were alive, with 3-year survival of 55.5%; median follow-up of surviving patients was 910 days (range, 68-2022). The allergic syndrome developed in five patients, with the cumulative incidence of new allergies at 2 years of 18.4% (95% confidence interval, 10.8-26). The median time to onset of new allergy after transplantation was 298 days (range, 250-809). CONCLUSIONS: Allergy development has been linked to a delayed maturation of the immune system in several studies. We present the first case series of patients who had new allergies after CBT. Further study of this novel complication as well as counseling of patients after CBT would be important.
Subject(s)
Cord Blood Stem Cell Transplantation , Hematologic Neoplasms/epidemiology , Hematologic Neoplasms/therapy , Hypersensitivity/epidemiology , Postoperative Complications/epidemiology , Time Factors , Adolescent , Adult , Child , Child, Preschool , Female , Follow-Up Studies , Hematologic Neoplasms/mortality , Humans , Hypersensitivity/etiology , Hypersensitivity/mortality , Incidence , Infant , Male , Middle Aged , Postoperative Complications/mortality , Prospective Studies , Survival Analysis , Young AdultABSTRACT
OBJECTIVES: Few data on the incidence, aetiology, clinical features and management of patients with acute allergic reactions presenting to the Emergency Department are currently available. The aim of the study was to report the annual experience of a single Italian adult Emergency Department about anaphylaxis. PATIENTS AND METHODS: This is a retrospective, case-based study of adult patients attending the Emergency Department in Alessandria, Italy, during the years 2009-2010. We evaluated the medical records of patients satisfying diagnostic codes involving acute allergic reactions. Incidence, demographic data, causative agents, clinical features, management and outcome were reported. RESULTS: 390 patients with acute allergic reactions were evaluated during the year, corresponding to 0.7% of all Emergency Department visits. Causative agents were recognized in 55.1% of patients and more commonly included drugs (26.9%), insects (14.8%) and foods (8.9%). Cutaneous features were the single most common clinical presentation although two or more clinical features were frequently reported (17.7%). Anaphylaxis was diagnosed in 4.6% of patients. After therapy and a period of monitoring, 92.8% of patients were discharged directly from the Emergency Department, 7.0% were admitted and one patient died, corresponding to a fatality rate of 0.2%. CONCLUSIONS: Acute allergic reactions are common diseases referring to our Emergency Department. In the half of cases a precipitant agent was identified and cutaneous and/or mucosal changes were often the first feature. Most patients were definitely treated and discharged but about 7.0% of patients required hospitalisation. Observation Unit and Intermediate Care Unit were essential for clinical management of these patients.
Subject(s)
Emergency Service, Hospital , Hypersensitivity/therapy , Acute Disease , Adult , Analysis of Variance , Anaphylaxis/diagnosis , Anaphylaxis/epidemiology , Anaphylaxis/mortality , Anaphylaxis/therapy , Female , Hospital Mortality , Humans , Hypersensitivity/diagnosis , Hypersensitivity/epidemiology , Hypersensitivity/mortality , Incidence , Italy/epidemiology , Male , Patient Discharge , Retrospective Studies , Risk Factors , Time Factors , Treatment OutcomeSubject(s)
Biocompatible Materials/adverse effects , Brain Edema/diagnosis , Craniotomy/adverse effects , Craniotomy/methods , Hypersensitivity/diagnosis , Meningeal Neoplasms/surgery , Meningioma/surgery , Postoperative Complications/diagnosis , Prostheses and Implants , Titanium/adverse effects , Brain/pathology , Brain Edema/mortality , Brain Edema/pathology , Death, Sudden/pathology , Fatal Outcome , Female , Frontal Bone/pathology , Frontal Bone/surgery , Humans , Hypersensitivity/mortality , Hypersensitivity/pathology , Meningeal Neoplasms/mortality , Meningioma/mortality , Middle Aged , Postoperative Complications/mortality , Postoperative Complications/pathology , Reoperation , Tomography, X-Ray ComputedSubject(s)
Cause of Death , Hypersensitivity/mortality , Drug Hypersensitivity/mortality , Humans , Intraoperative Period , Male , Middle AgedABSTRACT
BACKGROUND: Clinical outcomes after stent placement in patients with a history of metal allergy remain incompletely understood. We performed a single-center retrospective study to evaluate such outcomes. METHODS AND RESULTS: Twenty-nine allergic patients who underwent coronary stent implantation were compared with a nonallergic group (n=250) matched for demographics and a propensity score for allergy to metal. Hypersensitivity to nickel was reported in 26 of 29 and chromium in 9 of 29. Patch testing performed in 11 of 29 patients was positive in all. Comparing allergy versus control subjects, there were no differences in number of segments treated (1.4±0.7 versus 1.5±0.7), stents placed (1.7±1.1 versus 1.6±0.9), and frequency of drug-eluting stent usage (52% versus 60%). In-hospital death (0% versus 0%), myocardial infarction (MI, 4% versus 3%, P=0.27), and 30-day death (3% versus 0%, P=0.53) and MI (3% versus 4%, P=0.71) were statistically similar. There were no differences in 4-year death (12% versus 13%), target lesion revascularization (TLR, 13 versus 17%, P=0.54), or death/MI/TLR (24% versus 34%, P=0.20). Clinically driven repeat angiography in 12 of 29 allergy patients revealed binary restenosis rates of 27% in bare metal stents and 0% in drug-eluting stents, with mean diameter in-stent restenosis of 36% and 8%, respectively. There was no change in circulating eosinophil and lymphocyte counts after stenting in the allergy group (0.19-0.20, P=0.67, and 1.90-1.79, P=0.59, respectively). CONCLUSIONS: A history of metal allergy was not associated with adverse early or late outcomes in this single-center study.